Zobrazeno 1 - 6
of 6
pro vyhledávání: '"HDAC Inhibitor AR-42"'
Autor:
Ming Poi, Wenjun Ni, Flavia Pichiorri, Mitch A. Phelps, Jiang Wang, Douglas W. Sborov, Don M. Benson, Pierluigi Porcu, Craig C. Hofmeister, Joseph M. Flynn, Robert A. Baiocchi, Erinn M. Hade, Amir Mortazavi, Christopher C. Coss, Soun Khountham, Alessandro Canella, John C. Byrd, Xiaokui Mo, Leslie A. Andritsos, Beth A. Christian, Zhongfa Liu
Publikováno v:
Leukemia & Lymphoma. 58:2310-2318
Histone deacetylase inhibitors (HDACi) have proven activity in hematologic malignancies, and their FDA approval in multiple myeloma (MM) and T-cell lymphoma highlights the need for further development of this drug class. We investigated AR-42, an ora
Autor:
Luciano Cascione, Jessica Consiglio, Nicola Zanesi, Yvonne A. Efebera, Lara Rizzotto, Andrew Stiff, Flavia Pichiorri, Alessandro Canella, Balveen Kaur, Enrico Caserta, John C. Byrd, Hector Cordero Nieves, Hanna S. Radomska, Xiaokui Mo, Volinia Stefano, Emily Smith, Craig C. Hofmeister, Douglas W. Sborov
Publikováno v:
Oncotarget
Multiple myeloma (MM) is a hematological malignancy of plasma cells in the bone marrow. Despite multiple treatment options, MM is inevitably associated with drug resistance and poor outcomes. Histone deacetylase inhibitors (HDACi's) are promising nov
Publikováno v:
Biochemical and biophysical research communications. 463(4)
In the current study, we investigated the potential activity of AR-42, a novel histone deacetylase (HDAC) inhibitor, against colon cancer cells. Our in vitro results showed that AR-42 induced ceramide production, exerted potent anti-proliferative and
Autor:
Flavia Pichiorri, Luciano Cascione, Yvonne A. Efebera, Michael R. Grever, Douglas W. Sborov, John C. Byrd, Don M. Benson, Jessica Consiglio, Emily Smith, Craig C. Hofmeister, Wenjun Ni, Mo Xiaokui, Zhongfa Liu, Alessandro Canella, Lara Rizzotto, Hector M. Cordero-Nieves
Publikováno v:
Blood. 124:3377-3377
Introduction: The first FDA-approved deacetylase inhibitor (HDACi), suberoylanilide hydroxamic acid (SAHA, Vorinostat), was shown to be effective in vitro by a number of anti-neoplastic mechanisms. Despite minimal single-agent activity in multiple my
Autor:
Ching-Shih Chen, Ralf Bundschuh, Yu-Chou Tseng, Samuel K. Kulp, Tanios Bekaii-Saab, Wei He, Guido Marcucci, Pearlly S. Yan, Denis C. Guttridge, I-Lu Lai, David Frankhouser
Publikováno v:
Cancer Research. 74:5540-5540
Background: Cachexia occurs in more than 50% of cancer patients. Cachexia is characterized by severe loss of weight and skeletal muscle that is not reversed by nutritional support, and contributes significantly to morbidity and mortality. The develop
Autor:
Ching-Shih Chen, Samuel K. Kulp, Jaime F. Modiano, Cheryl A. London, William C. Kisseberth, Sridhar Murahari, Aimee L. Jalkanen
Publikováno v:
BMC Cancer
Background Osteosarcoma (OS) is the most common primary bone tumor in both humans and dogs and is the second leading cause of cancer related deaths in children and young adults. Limb sparing surgery along with chemotherapy has been the mainstay of tr